Debate – Fixed Duration Versus Until Progression: How Long Should the Initial Treatment of Myeloma Last?

The introduction of new treatment options in multiple myeloma (MM) has led to marked improvements in overall outcomes of patients. Attempts to make further improvements have focused on understanding the biology of MM, finding new treatment options, and on optimizing treatment outcomes with currently available therapies such as various combinations of available drugs and modifying treatment duration. A uniform myeloma treatment approach cannot be applied to all patients as the molecular characteristics of MM vary from one patient to another.  Therefore, recognizing the pros and cons of fixed duration versus therapy until progression will help clinicians adapt treatment strategies to match individual patient needs.

This information was originally presented at the NCCN 2019 Annual Congress: Hematologic Malignancies™  held in San Francisco, CA, on September 27-28, 2019.

Target Audience

This educational program is designed to meet the educational needs of the interprofessional oncology care team, including: physicians/oncologists, nurses, physician assistants, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Summarize the evidence from recent clinical trials supporting the use of targeted therapy for patients with newly diagnosed chronic lymphocytic leukemia. 
  • Recognize the emerging role of IGHV mutation status in the selection of first-line therapy, and identify patients with newly diagnosed chronic lymphocytic leukemia who could be candidates for chemoimmunotherapy.
  • Develop an individualized treatment plan for patients with newly diagnosed chronic lymphocytic leukemia based on the disease-specific and patient-specific characteristics.
Additional information
Supporters: 


This activity is supported by educational grants from: 

  • Agios Pharmaceuticals
  • AstraZeneca
  • BeiGene, Ltd.
  • Celgene Corporation
  • Coherus Biosciences
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Seattle Genetics, Inc.
  • Servier Pharmaceuticals, LLC
  • Takeda Oncology

This activity is supported by educational funding provided by Amgen.

This activity is supported by an independent educational grant from AbbVie.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.82 ANCC contact hours
  • 0.75 Participation
Course opens: 
11/01/2019
Course expires: 
10/31/2020
Cost:
$0.00

Facilitated by:
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

Presented by:
Yvonne A. Efebera, MD, MPH
The Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute

Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center

Panelists:    
Muhamed Baljevic, MD
Fred & Pamela Buffett Cancer Center

Jorge J. Castillo, MD
Dana-Farber Cancer Institute

Michaela Liedtke, MD
Stanford Cancer Institute

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures 
The faculty listed below discloses the following relevant financial relationships:

Andrew D. Zelenetz, MD, PhD
 AbbVie, Inc.: Consulting Fee; Scientific Advisor
 Adaptive Biotechnologies Corporation: Consulting Fee
 Amgen Inc.: Consulting Fee
 AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
 BeiGene: Grant/Research Support; Other Financial Benefit
 Celgene Corporation: Consulting Fee
 Genentech, Inc./Roche Laboratories, Inc.: Consulting Fee
 Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support 
 Janssen Pharmaceutica Products, LP: Consulting Fee 
 MEI Pharma Inc.: Grant/Research Support
 MorphoSys AG: Scientific Advisor
 Novartis Pharmaceuticals Corporation: Consulting Fee 
 Pharmacyclics: Consulting Fee
 Roche Laboratories, Inc.: Grant/Research Support

Yvonne A. Efebera, MD, MPH
 Akcea Therapeutics: Scientific Advisor
 Janssen Pharmaceutica Products, LP: Honoraria
 Takeda Pharmaceuticals North America, Inc.: Honoraria 

Muhamed Baljevic, MD
 Cardinal Health: Consulting Fee
 Karyopharm Therapeutics:Scientific Advisor
 Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Scientific Advisor 

Jorge J. Castillo, MD
 AbbVie, Inc.: Consulting Fee; Grant/Research Support
 BeiGene: Consulting Fee; Grant/Research Support
 Janssen Pharmaceutica Products, LP: Consulting Fee; Grant/Research Support
 Pharmacyclics: Consulting Fee; Grant/Research Support
 TG Therapeutics, Inc.: Grant/Research Support

Michaela Liedtke, MD
 Agios, Inc.: Grant/Research Support
 Amgen Inc.: Grant/Research Support; Consulting Fee
 bluebird bio, Inc.: Grant/Research Support
 Celator Pharmaceuticals: Grant/Research Support
 Celgene Corporation: Grant/Research Support; Scientific Advisor
 Genentech, Inc.: Grant/Research Support
 Gilead Sciences, Inc.: Grant/Research Support
 Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
 Jazz Pharmaceuticals Inc.: Scientific Advisor
 Pfizer Inc.: Grant/Research Support
 Prothena: Grant/Research Support
 Takeda Pharmaceuticals North America, Inc.: Grant/Research Support

The faculty listed below discloses no relevant financial relationships: 

Nina Shah, MD 

NCCN Staff Disclosures 

The NCCN Activity Planning staff listed below discloses no relevant financial relationships: 
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair; Kathy Ann Smith, CHCP 

The NCCN Leadership listed below discloses no relevant financial relationships: 
Robert W. Carlson, MD; Wui-Jin Koh, MD; Gary J. Weyhmuller, MBA, SPHR  

The NCCN Clinical staff listed below discloses no relevant financial relationships: 
Jennifer Keller; Rashmi Kumar, PhD

 In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physicians 
NCCN designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses 
NCCN designates this educational activity for a maximum of .82 contact hours. 

Pharmacists
NCCN designates this knowledge-based continuing education activity for .75 contact hours (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-19-095-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Catergory 1 CME credit for activities planned in accordance with AAPA CME criteria. This activity is designated for .75 AAPA Catergory 1 CME credits. Approval is valid until October 31, 2020. PAs should only claim credit commensurate with the extent of their participation. 

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.82 ANCC contact hours
  • 0.75 Participation

Accreditation Period

Course opens: 
11/01/2019
Course expires: 
10/31/2020

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: